Navigation Links
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Date:9/26/2007

tion. Japan is the 2nd largest national ESRD market after the United States with approximately 250,000 patients receiving dialysis.

Keryx holds a worldwide license (except for the Asian Pacific Region, but including Japan) to Zerenex(TM) from Panion & BF Biotech, Inc. Keryx is actively engaged in the development of Zerenex(TM) for the United States and is considering additional potential sublicenses in other parts of the world. Zerenex(TM), an oral, iron-based compound that has the capacity to bind to phosphorous and form non-absorbable complexes, has the potential to be an effective and safe treatment in lowering and/or maintaining serum phosphorus levels <5.5 mg/dL in patients with ESRD and hyperphosphatemia.

"We are pleased to have entered into this relationship with JT and Torii," stated Michael S. Weiss, Chairman and CEO of Keryx, who continued, "They have proven themselves to be ideal partners for smaller U.S.-based biotechnology companies seeking development and commercial partners in Japan. We are excited that they have chosen our phosphate binder for commercialization in Japan. We are committed to bringing forward globally this novel product and we are confident that by working together with JT and Torii we will be successful in bringing this valuable treatment option to patients in Japan."

"This arrangement with JT and Torii confirms our belief that there is a significant need for a novel phosphate binder like Zerenex(TM) and we look forward to working with our new partners moving the product forward in Japan," stated Ken Hoberman, head of Business Development for Keryx.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as K
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... -- , Collaboration with the U.S. ... in treatment of mastitis , Major ... begin in the second half 2013 ... Limited (ASX: POH, OTCQX: PPGNY) will collaborate with ... (ARS) to develop and trial products targeting the serious ...
(Date:5/20/2013)... , May 20, 2013 Today, at the ... Francisco , James McGough , ... at the Semel Institute for Neuroscience and Human Behavior ... Medicine at the University of California Los Angeles (UCLA), ... and Adolescent Psychopharmacology and ADHD at UCLA, presented the ...
(Date:5/20/2013)... 2013 With bed bugs' presence come problems ... bed bugs need to be eliminated, one must make sure ... person's health. And so to help bed bug sufferers get ... rid of bed bugs without using harmful pesticides. In ... it called Bed Bug Bully. , According to My Cleaning ...
(Date:5/20/2013)... 20, 2013 Rhythm announced today the results ... the company,s novel ghrelin agonist for the treatment of ... demonstrated that RM-131 significantly accelerates early gastric emptying and ... patients with diabetic gastroparesis. The findings were presented at ... Orlando and recently published in Clinical ...
Breaking Biology Technology:Phosphagenics Signs Research Agreement with the Agricultural Research Service 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... Transgene,(Euronext Paris: FR0005175080) announces promising preliminary data from,the ... as an adjunct to first line chemotherapy in ... This on-going trial is a randomized, open label ... TG4010 in combination with cisplatin and,gemcitabine compared to ...
... full year and fourth quarter 2007 preservation services and, ... to approximately $93.7 million for the year and ... 10 CryoLife, Inc. (NYSE: CRY ),a biomaterials, ... services and product revenues for 2007 were,approximately $93.7 million ...
... Berman Sobol Shapiro LLP,( http://www.hbsslaw.com/cellcyte.htm ) today ... CellCyte (OTC Bulletin Board: CCYG) for potential,violations ... after CellCyte,s shares plunged 55 percent,after news ... Gary,Reys, educational and professional credentials., CellCyte,s ...
Cached Biology Technology:Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3CryoLife Announces Record Preservation Services and Product Revenues for 2007 2CryoLife Announces Record Preservation Services and Product Revenues for 2007 3CryoLife Announces Record Preservation Services and Product Revenues for 2007 4Hagens Berman Sobol Shapiro Investigating CellCyte 2
(Date:5/17/2013)... residents of all ages will celebrate the science ... on our daily lives during the inaugural Atlanta ... and educators from local museums, corporations, K-12 schools ... 40 different events for children and adults at ... http://atlantasciencefestival.org . , The annual Atlanta Science ...
(Date:5/17/2013)... Federation of American Societies for Experimental Biology (FASEB) released ... Health (NIH) funding trends highlighting the devastating impact of ... The FASEB analysis follows a May 15th Senate Appropriations ... who testified that the $1.6 billion cut the agency ... a substantial impact on the scientific community." , ...
(Date:5/16/2013)... closer to a fast food restaurant had a higher ... away from fast food, according to researchers at The ... association was particularly strong among those with a lower ... the American Journal of Public Health indicates ... food restaurant, and among lower-income African-Americans, the density, or ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... - Bacteria are able to build camouflaged homes for themselves inside ... cellular process. , Purdue University ... from the bacteria Legionella pneumophila , which causes Legionnaires disease, ... the cell for use in building and disguising a large structure ...
... This press release is available in French . ... 19th -Century Montreal in two major ways, according to research ... infants from food and water contaminated by fecal bacteria, while ... the health of mothers as well as their subsequent children. ...
... (DOE),s Lawrence Berkeley National Laboratory (Berkeley Lab), through a ... a special line of human breast cells, have found ... ionizing radiation, cancer risks may not be directly proportional ... biological damage from ionizing radiation - the linear-no-threshold hypothesis ...
Cached Biology News:Purdue scientists reveal how bacteria build homes inside healthy cells 2Purdue scientists reveal how bacteria build homes inside healthy cells 3Breastfeeding saved babies in 19th century Montreal 2Breastfeeding saved babies in 19th century Montreal 3New take on impacts of low dose radiation 2New take on impacts of low dose radiation 3New take on impacts of low dose radiation 4
... Kit, 50 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
... reagents for the isolation of genomic DNA. ... the isolation of genomic DNA from blood. ... the isolation of genomic DNA from plants. ... be used for restriction endonuclease digestion Southern ...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Biology Products: